Drug Profile
E2F-1 gene therapy
Latest Information Update: 29 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Gene therapies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 24 Jun 1999 New profile
- 24 Jun 1999 Preclinical development for Cancer in USA (Unknown route)